医薬品受託製造開発機関（CDMO）アウトソーシングの世界市場：小分子、生物製剤

LINEで送る

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Small molecules – Market size and forecast 2018-2023

Biologics – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

APAC – Market size and forecast 2018-2023

South America – Market size and forecast 2018-2023

MEA – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Growing use of analytics by CDMOs

Growing demand for CDMOs for cell and gene therapies

Increasing market consolidation

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Aenova Holding GmbH

Almac Group Ltd.

Catalent Inc.

FAMAR Health Care Services

FAREVA SA

Lonza Group Ltd.

Recipharm AB

Siegfried Holding AG

The Lubrizol Corp.

Thermo Fisher Scientific Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Vendors: Key product offerings

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ billions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Product – Market share 2018-2023 (%)

Exhibit 19: Comparison by product

Exhibit 20: Small molecules – Market size and forecast 2018-2023 ($ billions)

Exhibit 21: Small molecules – Year-over-year growth 2019-2023 (%)

Exhibit 22: Biologics – Market size and forecast 2018-2023 ($ billions)

Exhibit 23: Biologics – Year-over-year growth 2019-2023 (%)

Exhibit 24: Market opportunity by product

Exhibit 25: Customer landscape

Exhibit 26: Market share by geography 2018-2023 (%)

Exhibit 27: Geographic comparison

Exhibit 28: North America – Market size and forecast 2018-2023 ($ billions)

Exhibit 29: North America – Year-over-year growth 2019-2023 (%)

Exhibit 30: Europe – Market size and forecast 2018-2023 ($ billions)

Exhibit 31: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 32: APAC – Market size and forecast 2018-2023 ($ billions)

Exhibit 33: APAC – Year-over-year growth 2019-2023 (%)

Exhibit 34: South America – Market size and forecast 2018-2023 ($ billions)

Exhibit 35: South America – Year-over-year growth 2019-2023 (%)

Exhibit 36: MEA – Market size and forecast 2018-2023 ($ billions)

Exhibit 37: MEA – Year-over-year growth 2019-2023 (%)

Exhibit 38: Key leading countries

Exhibit 39: Market opportunity

Exhibit 40: Impact of drivers and challenges

Exhibit 41: Vendor landscape

Exhibit 42: Landscape disruption

Exhibit 43: Vendors covered

Exhibit 44: Vendor classification

Exhibit 45: Market positioning of vendors

Exhibit 46: Aenova Holding GmbH – Vendor overview

Exhibit 47: Aenova Holding GmbH – Service segments

Exhibit 48: Aenova Holding GmbH – Organizational developments

Exhibit 49: Aenova Holding GmbH – Key offerings

Exhibit 50: Almac Group Ltd. – Vendor overview

Exhibit 51: Almac Group Ltd. – Product segments

Exhibit 52: Almac Group Ltd. – Organizational developments

Exhibit 53: Almac Group Ltd. – Key offerings

Exhibit 54: Catalent Inc. – Vendor overview

Exhibit 55: Catalent Inc. – Business segments

Exhibit 56: Catalent Inc. – Organizational developments

Exhibit 57: Catalent Inc. – Geographic focus

Exhibit 58: Catalent Inc. – Segment focus

Exhibit 59: Catalent Inc. – Key offerings

Exhibit 60: FAMAR Health Care Services – Vendor overview

Exhibit 61: FAMAR Health Care Services – Service segments

Exhibit 62: FAMAR Health Care Services – Organizational developments

Exhibit 63: FAMAR Health Care Services – Key offerings

Exhibit 64: FAREVA SA – Vendor overview

Exhibit 65: FAREVA SA – Business segments

Exhibit 66: FAREVA SA – Organizational developments

Exhibit 67: FAREVA SA – Key offerings

Exhibit 68: Lonza Group Ltd. – Vendor overview

Exhibit 69: Lonza Group Ltd. – Business segments

Exhibit 70: Lonza Group Ltd. – Organizational developments

Exhibit 71: Lonza Group Ltd. – Geographic focus

Exhibit 72: Lonza Group Ltd. – Segment focus

Exhibit 73: Lonza Group Ltd. – Key offerings

Exhibit 74: Recipharm AB – Vendor overview

Exhibit 75: Recipharm AB – Business segments

Exhibit 76: Recipharm AB – Organizational developments

Exhibit 77: Recipharm AB – Geographic focus

Exhibit 78: Recipharm AB – Segment focus

Exhibit 79: Recipharm AB – Key offerings

Exhibit 80: Siegfried Holding AG – Vendor overview

Exhibit 81: Siegfried Holding AG – Product segments

Exhibit 82: Siegfried Holding AG – Organizational developments

Exhibit 83: Siegfried Holding AG – Segment focus

Exhibit 84: Siegfried Holding AG – Key offerings

Exhibit 85: The Lubrizol Corp. – Vendor overview

Exhibit 86: The Lubrizol Corp. – Business segments

Exhibit 87: The Lubrizol Corp. – Organizational developments

Exhibit 88: The Lubrizol Corp. – Key offerings

Exhibit 89: Thermo Fisher Scientific Inc. – Vendor overview

Exhibit 90: Thermo Fisher Scientific Inc. – Business segments

Exhibit 91: Thermo Fisher Scientific Inc. – Organizational developments

Exhibit 92: Thermo Fisher Scientific Inc. – Geographic focus

Exhibit 93: Thermo Fisher Scientific Inc. – Segment focus

Exhibit 94: Thermo Fisher Scientific Inc. – Key offerings

Exhibit 95: Validation techniques employed for market sizing

Exhibit 96: Definition of market positioning of vendors

【関連データ：市場動向/規模/将来展望等のグローバル分析データ】

  1. 神経筋疾患治療法の世界市場：生物製剤、小分子
  2. ベーチェット病治療法の世界市場：小分子、生物製剤
  3. アテローム性動脈硬化症治療法の世界市場：小分子、生物製剤
  4. 乾癬性関節炎治療法の世界市場：生物製剤、小分子
※当サイトのレポート紹介カバレッジ
■産業：医療、IT、電子、自動車、産業機械、建設、消費財、食品、化学、材料、エネルギー、金融、サービスなど多様
■地域：世界市場、アジア市場、中国市場、欧州市場、北米市場、中南米市場、中東市場、アフリカ市場など全世界
■レポート種類：市場動向、規模、占有率、トレンド、将来展望、未来予測、業界分析、産業分析、企業分析、事業機会分析、戦略提言など多様